MDM2 inhibitor Idasanutlin potentiate therapeutic agents in Diffuse Large B-Cell Lymphoma by targeting MDM2 and XIAP

被引：0
|
作者：
Gu, Juan J. [1 ]
Thompson, Samuel [1 ]
Mavis, Cory [1 ]
Torka, Pallawi [1 ]
Hernandez-Ilizaliturri, Francisco [1 ]
机构：
[1] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-2404
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2404
引用
收藏
页数：2
相关论文
共 50 条
  • [21] MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a
    Tinhofer, I.
    Gryshchenko, I.
    Stoecher, M.
    Hofbauer, S.
    Daniel, P. T.
    Greil, R.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 347 - 347
  • [22] MDM2 as a cancer therapeutic target - Editorial
    Zhang, RW
    [J]. CURRENT CANCER DRUG TARGETS, 2005, 5 (01) : 1 - 2
  • [23] Radiosensitization of solid tumor cell lines by an MDM2 inhibitor
    Cerna, David
    Li, Hongyun
    Flaherty, Siobhan
    Carter, Donna
    Coleman, C. Norman
    Yoo, Stephen
    [J]. CANCER RESEARCH, 2011, 71
  • [24] MDM2 splice variants and their therapeutic implications
    Harris, LC
    [J]. CURRENT CANCER DRUG TARGETS, 2005, 5 (01) : 21 - 26
  • [25] Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment
    Gu, Lubing
    Zhang, Hailong
    Liu, Tao
    Zhou, Sheng
    Du, Yuhong
    Xiong, Jing
    Yi, Sha
    Qu, Cheng-Kui
    Fu, Haian
    Zhou, Muxiang
    [J]. CANCER CELL, 2016, 30 (04) : 623 - 636
  • [26] AKT - Mediated serine 166 phosphorylation of MDM2 in anaplastic large cell lymphoma
    Giaslakiotis, K
    Drakos, E
    Tian, L
    Claret, FX
    Medeiros, LJ
    Rassidakis, GZ
    [J]. LABORATORY INVESTIGATION, 2006, 86 : 227A - 227A
  • [27] Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
    Li, Qin
    Lozano, Guillermina
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (01) : 34 - 41
  • [28] Idasanutlin MDM2 (Hdm2) inhibitor Treatment of acute myeloid leukemia Hematological cancer therapy
    Gras, J.
    [J]. DRUGS OF THE FUTURE, 2018, 43 (02) : 87 - 96
  • [29] MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors
    Howard, Thomas P.
    Arnoff, Taylor E.
    Song, Melinda R.
    Giacomelli, Andrew O.
    Wang, Xiaofeng
    Hong, Andrew L.
    Dharia, Neekesh V.
    Wang, Su
    Vazquez, Francisca
    Minh-Tam Pham
    Morgan, Ann M.
    Wachter, Franziska
    Bird, Gregory H.
    Kugener, Guillaume
    Oberlick, Elaine M.
    Rees, Matthew G.
    Tiv, Hong
    Hwang, Justin H.
    Walsh, Katherine H.
    Cook, April
    Krill-Burger, John M.
    Tsherniak, Aviad
    Gokhale, Prafulla C.
    Park, Peter J.
    Stegmaier, Kimberly
    Walensky, Loren D.
    Hahn, William C.
    Roberts, Charles W.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [30] Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b
    Ishizawa, Jo
    Nakamaru, Kenji
    Seki, Takahiko
    Tazaki, Koichi
    Kojima, Kensuke
    Chachad, Dhruv
    DiNardo, Courtney D.
    Pierce, Sherry
    Patel, Keyur P.
    Tse, Archie
    Davis, R. Eric
    Rao, Arvind
    Andreeff, Michael
    [J]. BLOOD, 2016, 128 (22)
12345